Research ExplorerPublicationsStenting with Acclino® (flex) for symptomatic intracranial s...

Stenting with Acclino® (flex) for symptomatic intracranial stenosis as secondary stroke prevention

Standard

Stenting with Acclino® (flex) for symptomatic intracranial stenosis as secondary stroke prevention. / Meyer, Lukas; Leischner, Hannes; Thomalla, Goetz; Krause, Lars Udo; Lowens, Stephan; Rothaupt, Jan; Hanning, Uta; Buhk, Jan Hendrik; Fiehler, Jens; Chapot, René; Stracke, Christian Paul; Bester, Maxim.

In: J NEUROINTERV SURG, Vol. 12, No. 11, 11.2020, p. 1127-1131.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Meyer, L, Leischner, H, Thomalla, G, Krause, LU, Lowens, S, Rothaupt, J, Hanning, U, Buhk, JH, Fiehler, J, Chapot, R, Stracke, CP & Bester, M 2020, 'Stenting with Acclino® (flex) for symptomatic intracranial stenosis as secondary stroke prevention', J NEUROINTERV SURG, vol. 12, no. 11, pp. 1127-1131. https://doi.org/10.1136/neurintsurg-2019-015744

APA

Meyer, L., Leischner, H., Thomalla, G., Krause, L. U., Lowens, S., Rothaupt, J., Hanning, U., Buhk, J. H., Fiehler, J., Chapot, R., Stracke, C. P., & Bester, M. (2020). Stenting with Acclino® (flex) for symptomatic intracranial stenosis as secondary stroke prevention. J NEUROINTERV SURG, 12(11), 1127-1131. https://doi.org/10.1136/neurintsurg-2019-015744

Vancouver

Meyer L, Leischner H, Thomalla G, Krause LU, Lowens S, Rothaupt J et al. Stenting with Acclino® (flex) for symptomatic intracranial stenosis as secondary stroke prevention. J NEUROINTERV SURG. 2020 Nov;12(11):1127-1131. https://doi.org/10.1136/neurintsurg-2019-015744

Bibtex

@article{87498e8b78cb4ad6a92a323204b289df,
title = "Stenting with Acclino{\textregistered} (flex) for symptomatic intracranial stenosis as secondary stroke prevention",
abstract = "BACKGROUND AND PURPOSE: Stroke recurrence is high in patients with symptomatic intracranial stenosis despite best medical treatment. Based on evidence from past studies using previous stent generations, elective intracranial stenting (eICS) is considered in a minority of patients. This study aims to report on experience performing eICS with a novel device combination.METHODS: We retrospectively reviewed data from three high volume stroke centers and analyzed patients that were treated with eICS for symptomatic intracranial stenosis using the Acclino{\textregistered} (flex) stent and the NeuroSpeed{\textregistered} balloon catheter (Acandis GmbH, Pforzheim, Germany). Study endpoints were periprocedural rates of stroke regardless of territory or death at discharge and at the time of follow-up after eICS. Safety evaluation included asymptomatic and symptomatic intracranial hemorrhage, serious adverse events related to the intervention, and evaluation of stent patency at the time of follow-up.RESULTS: The median age of patients that met the inclusion criteria (n=76) was 69 years. Target vessels were located in the anterior circulation in 55.3% (42/76) of patients. The periprocedural stroke rate was 6.5% (fatal stroke 2.6%; non-fatal stroke 3.9%) at discharge after eICS. Asymptomatic intracranial hemorrhage was observed in 5.2% (4/76) of patients. Follow-up DSA revealed in-stent restenosis of 25% (15/60), and percutaneous transluminal angioplasty was performed again in 11.6% (7/60) of patients.CONCLUSION: Stenting for symptomatic intracranial stenosis with the Acclino{\textregistered} (flex)/NeuroSpeed balloon{\textregistered} catheter seemed to be safe and reinforces eICS as an endovascular therapy option for secondary stroke prevention. Future studies are warranted to confirm these findings and investigate antithrombotic strategies and in-stent restenosis to minimize periprocedural complications and guarantee long term stent patency.",
author = "Lukas Meyer and Hannes Leischner and Goetz Thomalla and Krause, {Lars Udo} and Stephan Lowens and Jan Rothaupt and Uta Hanning and Buhk, {Jan Hendrik} and Jens Fiehler and Ren{\'e} Chapot and Stracke, {Christian Paul} and Maxim Bester",
note = "{\textcopyright} Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2020",
month = nov,
doi = "10.1136/neurintsurg-2019-015744",
language = "English",
volume = "12",
pages = "1127--1131",
journal = "J NEUROINTERV SURG",
issn = "1759-8478",
publisher = "BMJ PUBLISHING GROUP",
number = "11",

}

RIS

TY - JOUR

T1 - Stenting with Acclino® (flex) for symptomatic intracranial stenosis as secondary stroke prevention

AU - Meyer, Lukas

AU - Leischner, Hannes

AU - Thomalla, Goetz

AU - Krause, Lars Udo

AU - Lowens, Stephan

AU - Rothaupt, Jan

AU - Hanning, Uta

AU - Buhk, Jan Hendrik

AU - Fiehler, Jens

AU - Chapot, René

AU - Stracke, Christian Paul

AU - Bester, Maxim

N1 - © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2020/11

Y1 - 2020/11

N2 - BACKGROUND AND PURPOSE: Stroke recurrence is high in patients with symptomatic intracranial stenosis despite best medical treatment. Based on evidence from past studies using previous stent generations, elective intracranial stenting (eICS) is considered in a minority of patients. This study aims to report on experience performing eICS with a novel device combination.METHODS: We retrospectively reviewed data from three high volume stroke centers and analyzed patients that were treated with eICS for symptomatic intracranial stenosis using the Acclino® (flex) stent and the NeuroSpeed® balloon catheter (Acandis GmbH, Pforzheim, Germany). Study endpoints were periprocedural rates of stroke regardless of territory or death at discharge and at the time of follow-up after eICS. Safety evaluation included asymptomatic and symptomatic intracranial hemorrhage, serious adverse events related to the intervention, and evaluation of stent patency at the time of follow-up.RESULTS: The median age of patients that met the inclusion criteria (n=76) was 69 years. Target vessels were located in the anterior circulation in 55.3% (42/76) of patients. The periprocedural stroke rate was 6.5% (fatal stroke 2.6%; non-fatal stroke 3.9%) at discharge after eICS. Asymptomatic intracranial hemorrhage was observed in 5.2% (4/76) of patients. Follow-up DSA revealed in-stent restenosis of 25% (15/60), and percutaneous transluminal angioplasty was performed again in 11.6% (7/60) of patients.CONCLUSION: Stenting for symptomatic intracranial stenosis with the Acclino® (flex)/NeuroSpeed balloon® catheter seemed to be safe and reinforces eICS as an endovascular therapy option for secondary stroke prevention. Future studies are warranted to confirm these findings and investigate antithrombotic strategies and in-stent restenosis to minimize periprocedural complications and guarantee long term stent patency.

AB - BACKGROUND AND PURPOSE: Stroke recurrence is high in patients with symptomatic intracranial stenosis despite best medical treatment. Based on evidence from past studies using previous stent generations, elective intracranial stenting (eICS) is considered in a minority of patients. This study aims to report on experience performing eICS with a novel device combination.METHODS: We retrospectively reviewed data from three high volume stroke centers and analyzed patients that were treated with eICS for symptomatic intracranial stenosis using the Acclino® (flex) stent and the NeuroSpeed® balloon catheter (Acandis GmbH, Pforzheim, Germany). Study endpoints were periprocedural rates of stroke regardless of territory or death at discharge and at the time of follow-up after eICS. Safety evaluation included asymptomatic and symptomatic intracranial hemorrhage, serious adverse events related to the intervention, and evaluation of stent patency at the time of follow-up.RESULTS: The median age of patients that met the inclusion criteria (n=76) was 69 years. Target vessels were located in the anterior circulation in 55.3% (42/76) of patients. The periprocedural stroke rate was 6.5% (fatal stroke 2.6%; non-fatal stroke 3.9%) at discharge after eICS. Asymptomatic intracranial hemorrhage was observed in 5.2% (4/76) of patients. Follow-up DSA revealed in-stent restenosis of 25% (15/60), and percutaneous transluminal angioplasty was performed again in 11.6% (7/60) of patients.CONCLUSION: Stenting for symptomatic intracranial stenosis with the Acclino® (flex)/NeuroSpeed balloon® catheter seemed to be safe and reinforces eICS as an endovascular therapy option for secondary stroke prevention. Future studies are warranted to confirm these findings and investigate antithrombotic strategies and in-stent restenosis to minimize periprocedural complications and guarantee long term stent patency.

U2 - 10.1136/neurintsurg-2019-015744

DO - 10.1136/neurintsurg-2019-015744

M3 - SCORING: Journal article

C2 - 32123006

VL - 12

SP - 1127

EP - 1131

JO - J NEUROINTERV SURG

JF - J NEUROINTERV SURG

SN - 1759-8478

IS - 11

ER -